Tag - Xylyx Bio

Patient-Derived Organoids Transform Precision Medicine

Ziad2022-11-25T14:02:27-05:00 Advances in cell culture techniques don’t just mean more accurate models, but more personal ones. For decades scientists have been trying to figure out how to grow cells, especially diseased ones, directly from patients, not only to better understand the mechanisms at play, but also to determine the best approach to cure or correct the malfunction. Today, scientists can grow human tumors in a variety of designer mice, some with human immune systems. Read more >>

XYLYX BIO releases highly physiologic 2D substrates for improved antifibrotic drug discovery

Ziad2022-11-25T14:02:28-05:00 New York-based Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH. Read more >>

4th Annual IPF Summit

Ziad2022-11-25T14:02:28-05:00 Xylyx Bio. to speak at the 4th Annual IPF Summer. Read more >>

Xylyx Bio releases advanced disease model system to improve cancer drug discovery

Ziad2022-11-25T14:02:38-05:00 Xylyx Bio, a leader in predictive disease models, today announced the release of its IN SITE™ Metastasis Kit, a highly physiologic system that contains complex site-specific microenvironments to provide scientists with much-needed insight into cancer disease biology and the efficacy of drug candidates. Read more >>

Interview with John O’Neil, Chief Scientific Officer of Xylyx

Ziad2022-11-25T14:02:38-05:00 An inspiration and candid conversation between Dr. Mayasari Lim and upcoming 3DHEALS2020 speaker John O’Neil, Chief Scientific Officer of Xylyx, a New York-based startup focusing on creating the perfect cell environment for a variety of biotech process including biofabrication/bioprinting, and tissue engineering. Read more >>

Xylyx Bio offers advanced lung models to accelerate COVID-19-related drug development

Ziad2022-11-25T14:02:38-05:00 Xylyx Bio, a pioneer in advanced biological systems for drug development, today announced availability of products that recreate the lung environment in vitro to provide a predictive model that brings much-needed insight into the efficacy of COVID-19-related drug candidates. Read more >>

Allevi Partners with Xylyx Bio to Create Liver Specific Bioinks

Ziad2022-11-25T14:02:39-05:00 ...Only a handful of researchers and companies around the world are tackling liver-specific bioinks, and one of them is now Allevi. The Philadelphia-based biotech company has now partnered with Xylyx Bio, a pioneer in physiomimetic biomaterials, to introduce new tissue-specific bioinks with Decellularized Extracellular Matrix (dECM). Read more >>

Xylyx Bio announces development of disease-specific cell culture products to accelerate anti-fibrotic drug discovery and screening

Ziad2022-11-25T14:03:26-05:00 Xylyx Bio, a pioneer in tissue-specific extracellular matrix biomaterials, today announced the development of substrates for anti-fibrotic drug discovery as the next stage of its pipeline of pre-clinical cell culture products. Read more >>

Xylyx Bio joins Advanced Regenerative Manufacturing Institute (ARMI) Consortium

Ziad2022-11-25T14:03:27-05:00 Xylyx Bio, a pioneer in physiomimetic biomaterials, today announced that it has joined the Advanced Regenerative Manufacturing Institute (ARMI), a public-private Manufacturing USA initiative that supports the manufacturing of engineered tissues and tissue-related technologies. Read more >>

Xylyx Bio Announces Global Expansion, Adds 9 International Distributors to Meet Growing Demand

Ziad2022-11-25T14:03:38-05:00 Xylyx Bio, a pioneer in physiomimetic cell culture, today announced that it is expanding globally to meet growing international demand for its physiologic cell culture products. Read more >>